INDICATION & USAGE: MONJUVI
(tafasitamab-cxix), in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

Skip to content

This site is for
US healthcare professionals

LONG-TERM DATA
FOR SECOND LINE+

MONJUVI is the only outpatient targeted immunotherapy for adult NTE patients with R/R DLBCL in 2L with 5-year data.1,2*

The 5-year analysis data from L-MIND have not been submitted to or reviewed by the FDA, and potential inclusion of these data in the final FDA-approved labeling has yet to be determined.

A DLBCL expert, Dr Hayder Saeed, discusses long-term results.

Watch now

*MONJUVI is a CD19-directed cytolytic monoclonal antibody.1

*MONJUVI is a CD19-directed cytolytic monoclonal antibody.1

Skip to NCCN Banner
2L Treatment Factors

Uncover factors that drive
2L treatment decisions

Learn more
MONJUVI Efficacy

Explore the L-MIND
clinical study results

See the data
Safety

Review the safety profile
of MONJUVI

Go now
BACK TO TOP
EXPAND